Verenigde Staten - Engels - NLM (National Library of Medicine)

a-s medication solutions - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - budesonide and formoterol fumarate dihydrate inhalation aerosol is indicated for the treatment of asthma in patients 6 years of age and older. budesonide and formoterol fumarate dihydrate inhalation aerosol should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta2-adrenergic agonist (laba). important limitations of use: budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema. budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is also indicated to reduce exacerbations of copd. budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is the only strength indicated for the treatment of copd. important limitat

Australië - Engels - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Ierland - Engels - HPRA (Health Products Regulatory Authority)

rowex ltd - budesonide; formoterol fumarate dihydrate - inhalation powder, pre-dispensed - 320/9 microgram(s) - formoterol and budesonide

Malta - Engels - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 4.5 µg budesonide 160 µg - drugs for obstructive airway diseases

Malta - Engels - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 9 µg budesonide 320 µg - drugs for obstructive airway diseases

Malta - Engels - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 4.5 µg budesonide 160 µg - drugs for obstructive airway diseases

Malta - Engels - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - formoterol fumarate, dihydrate, budesonide - inhalation powder - formoterol fumarate dihydrate 9 µg budesonide 320 µg - drugs for obstructive airway diseases

Malta - Engels - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - budesonide, formoterol fumarate, dihydrate - inhalation powder - budesonide 80 µg formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases

Malta - Engels - Medicines Authority

orion corporation orionintie 1, fi-02200 espoo, finland - budesonide, formoterol fumarate, dihydrate - prolonged-release tablet - budesonide 80 µg formoterol fumarate dihydrate 4.5 µg - drugs for obstructive airway diseases